title: Pharmacologic treatments for rosacea.
abstract: Rosacea represents a common and chronic inflammatory skin disorder. Clinical features include transient and permanent erythema, inflammatory papules and pustules, phymatous changes, and ocular signs and symptoms. Rosacea is generally classified into four subtypes and one variant. Subtype 1, erythematotelangiectatic rosacea, includes clinical features of flushing and persistent central facial erythema with or without telangiectasia. Subtype 2, papulopustular rosacea, is characterized by persistent central facial erythema with transient papules or pustules or both on the central face. Subtype 3, phymatous rosacea, includes thickening of the skin with irregular surface nodularities and enlargement. Subtype 4, ocular rosacea, includes inflammation of different parts of the eye and eyelid. A variant, granulomatous rosacea, is noninflammatory and is characterized by hard, brown, yellow, or red cutaneous papules or nodules of uniform size. Patients may present with more than one subtype, and each individual characteristic may fluctuate. There is debate whether rosacea progresses from one subtype over time or subtypes represent discreet entities. Defining clinical presentation and improved understanding of pathophysiology has resulted in identification of novel treatment approaches. This contribution outlines a rationale for treatment, highlights an evidence-based approach with approved treatments, and considers novel developments and off-license therapy available.
authors.affiliation: Department of Dermatology, Harrogate and District NHS Foundation Trust, Harrogate, United Kingdom. Electronic address: alison.layton@hdft.nhs.uk.
authors.forename: Alison M
authors.initials: AM
authors.lastname: Layton
mesh_terms: D004890:Erythema / Q000175:diagnosis; D005128:Eye Diseases / Q000209:etiology; D005483:Flushing / Q000175:diagnosis; D006801:Humans; D012393:Rosacea / Q000145:classification / Q000188:drug therapy* / Q000473:pathology